All News

Data underscored the efficacy of mavacamten in reducing eligibility for surgical intervention among patients with obstructive hypertrophic cardiomyopathy (oHCM).

Attending comprehensive sexuality education (CSE) was associated with increased access to HIV testing among adolescent girls, regardless of whether they were actively in school.

Milind Desai, MD, MBA, director of the Center for Hypertrophic Cardiomyopathy and medical director of the Center for Aortic Diseases, Cleveland Clinic, speaks on therapeutic implications of the VALOR-HCM late-breaking clinical trial findings presented Saturday at the American College of Cardiology's 71st Scientific Session.

Christopher Phillips, MD, a rheumatologist in Kentucky, discusses the back-and-forth that providers have with insurers in trying to get therapies approved for reimbursement.

This new analysis of data from the Swedish Heart Failure Registry involved an investigation into the relationship between therapy count and dosing on mortality and morbidity among patients with heart failure with reduced ejection fraction (HFrEF).

Implementing changes in a health system to promote biosimilar adoption is not easy, but by implementing a program, there could be substantial savings.

As potential new treatment options emerge for hidradenitis suppurativa (HS), an inflammatory condition, researchers emphasized the importance of clinicians being prepared to manage patients that have additional health factors.

Acknowledging the small number of genetic reports used in their study, the researchers attribute the scarce amount of data to a lack of resources and limited access to genetic screening across Africa.

The clinical effectiveness of chimeric antigen receptor (CAR) T-cell therapies adds a new weapon in the arsenal to treat patients with relapsed and refractory disease; however, they come with access, logistical, and reimbursement challenges that make it difficult to treat all the patients who could benefit.

The expanded use of axi-cel, sold as Yescarta, while not unexpected, nonetheless represents uncharted territory in cancer care.

Both fidaxomicin and vancomycin are recommended for treatment of Clostridioides difficile infections, but real-world data suggest fidaxomicin should be the go-to treatment option.

A recent report details the first reported case of an osteolytic lesion in polycythemia vera and reviews current literature on osteolytic lesions in myeloproliferative neoplasms (MPNs) overall.

Urge-to-cough and cough symptoms were the 2 main domains of a 51-item framework to measure cough severity.

Camille Hertzka, vice president, head of oncology, US Medical, AstraZeneca, discusses why so much excitement has been generated for the use of olaparib (Lynparza) in the first line for patients with metastatic castrate-resistant prostate cancer.

Melissa Johnson, MD, program director of lung cancer research at Sarah Cannon Research Institute, outlines the importance of diverse patient populations in cancer trials.

A recent review highlighted the benefits of conducting further research on surgical disease modification to slow the progression of Parkinson disease.

According to a recent study, patients with an exacerbation of chronic obstructive pulmonary disease (COPD) have greater risks of both subsequent exacerbations and mortality.

Zahra Mahmoudjafari, PharmD, BCOP, clinical pharmacy manager at the University of Kansas Health System, gives her take on what payers should keep in mind when dealing with chimeric antigen receptor (CAR) T-cell therapies.

Research shows that disease activity level did not correlate with fat mass percentage among individuals with rheumatoid arthritis (RA).

Value-based contracts are growing as drugs get more expensive and effective, but it’s still an emerging area with a lot of unknown and uncertainty.

NCCN guidelines are no longer “a group of monotherapy choices,” but selections that feature partners for endocrine therapy, highlighted William J. Gradishar, MD, of the Robert H. Lurie Comprehensive Cancer Center of Northwestern University.

Pipeline forecasting can provide payers better insight into which expensive specialty drugs coming down the pipeline they should be keeping their eyes on, according to Katie Lockhart, MA, manager at Magellan Health.

Chelsee Jensen, PharmD, pharmaceutical formulary manager at Mayo Clinic, explains how the process of implementing biosimilars may differ depending on practice size.

Coverage of our peer-reviewed research and news reporting in the health care and mainstream press.

Democrats and Republicans are near agreement on a $10 billion COVID-19 funding package; scientists perform the first complete, gapless sequence of a human genome; more than a third of high school students reported they experienced poor mental health during the pandemic.

Soumya Vishwanath, PharmD, senior manager of formulary strategy at Magellan Rx Management, highlighted the therapeutic gaps that need to be addressed to ensure that patients with behavioral health disorders are well cared for.

New research presented at the American College of Cardiology's 71st Annual Scientific Session & Expo highlights the high costs of heart failure in the United States and the benefits of healthy eating and exercise as preventive measures.

From taking part in clinical research at a local location to foregoing aggressive therapy in favor of quality of life, patients with cancer are seeking new options, said panelists at the 2022 Annual Conference of the National Comprehensive Cancer Network (NCCN).

In 2022 and 2023, there are a number of big therapies losing patent exclusivity, which opens the door to generics that could save as much as $30 billion.

Conversations are ongoing between CMS and patient advocates on how accountable care organizations (ACOs) and similar programs can better interface with beneficiaries.